标题
Involvement of substance P and the NK-1 receptor in human pathology
作者
关键词
Substance P, NK-1 receptor, NK-1 receptor antagonists, Molecular bases, Human pathology
出版物
AMINO ACIDS
Volume 46, Issue 7, Pages 1727-1750
出版商
Springer Nature
发表日期
2014-04-05
DOI
10.1007/s00726-014-1736-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo
- (2014) Michael Berger et al. JOURNAL OF HEPATOLOGY
- Neurogenic Exacerbation of Microglial and Astrocyte Responses to Neisseria meningitidis and Borrelia burgdorferi
- (2014) V. S. Chauhan et al. JOURNAL OF IMMUNOLOGY
- Safety of neurokinin-1 receptor antagonists
- (2013) Miguel Muñoz et al. Expert Opinion On Drug Safety
- Involvement of substance P and the NK-1 receptor in cancer progression
- (2013) Miguel Muñoz et al. PEPTIDES
- Substance P antagonist improves both obesity and asthma in a mouse model
- (2012) R. Ramalho et al. ALLERGY
- Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
- (2012) H. Saito et al. ANNALS OF ONCOLOGY
- Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain
- (2012) David Borsook et al. DRUG DISCOVERY TODAY
- Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study
- (2012) Daniele Santini et al. LANCET ONCOLOGY
- Peripheral substance P and neurokinin-1 receptors have a role in inflammatory and neuropathic orofacial pain models
- (2012) Fernanda C. Teodoro et al. NEUROPEPTIDES
- The substance P/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists
- (2012) Miguel Muñoz et al. PEPTIDES
- Recurrent major depressive disorder: Imbalance of neurokinin (NK)-1 and NK-2 receptor expression in monocytes
- (2012) Claudio Bardelli et al. PHARMACOLOGICAL RESEARCH
- Treatment with a Substance P Receptor Antagonist Is Neuroprotective in the Intrastriatal 6-Hydroxydopamine Model of Early Parkinson's Disease
- (2012) Emma Thornton et al. PLoS One
- Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
- (2012) I. N. Olver et al. SUPPORTIVE CARE IN CANCER
- Substance P Causes Seizures in Neurocysticercosis
- (2012) Prema Robinson et al. PLoS Pathogens
- Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
- (2011) F. D. Rodriguez et al. CURRENT MEDICINAL CHEMISTRY
- NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
- (2011) M. Munoz et al. CURRENT MEDICINAL CHEMISTRY
- Prophylactic and Therapeutic Targeting of the Neurokinin-1 Receptor Limits Neuroinflammation in a Murine Model of Pneumococcal Meningitis
- (2011) V. S. Chauhan et al. JOURNAL OF IMMUNOLOGY
- A Randomized, Placebo Controlled, Double Masked Phase IB Study Evaluating the Safety and Antiviral Activity of Aprepitant, a Neurokinin-1 Receptor Antagonist in HIV-1 Infected Adults
- (2011) Pablo Tebas et al. PLoS One
- Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial
- (2011) Muneer H Abidi et al. SUPPORTIVE CARE IN CANCER
- Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals
- (2010) Mark M Manak et al. AIDS
- A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
- (2010) M. Munoz et al. CURRENT MEDICINAL CHEMISTRY
- Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the rat
- (2010) Mikhail Kalinichev et al. EPILEPSIA
- The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines
- (2010) Miguel Muñoz et al. LABORATORY INVESTIGATION
- Artificial microRNA-based neurokinin-1 receptor gene silencing reduces alcohol consumption in mice
- (2010) Mi Na Baek et al. NEUROSCIENCE LETTERS
- Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy
- (2010) Sonja Ständer et al. PLoS One
- Neurokinin-1 receptors (NK1R:s), alcohol consumption, and alcohol reward in mice
- (2010) Annika Thorsell et al. PSYCHOPHARMACOLOGY
- Tachykinin Receptors as Therapeutic Targets in Stress-Related Disorders
- (2009) Karl Ebner et al. CURRENT PHARMACEUTICAL DESIGN
- Neurokinin 1 Receptor Mediates Membrane Blebbing in HEK293 Cells through a Rho/Rho-associated Coiled-coil Kinase-dependent Mechanism
- (2009) John Meshki et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
- (2009) Jørn Herrstedt et al. JOURNAL OF CLINICAL ONCOLOGY
- Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity
- (2008) B. M. Janelsins et al. BLOOD
- Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression
- (2008) Francisco Esteban et al. HISTOPATHOLOGY
- Cell motility through plasma membrane blebbing
- (2008) Oliver T. Fackler et al. JOURNAL OF CELL BIOLOGY
- Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours
- (2008) M.A. González Moles et al. ORAL ONCOLOGY
- Neurokinin 1 Receptor Antagonism as a Possible Therapy for Alcoholism
- (2008) D. T. George et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More